Eiger BioPharmaceuticals Current Cash

Eiger BioPharmaceuticals (EIGR) currently reports a current cash of $25M as of December 2023. That compares with $99M in the prior-year period — down 74.3% year over year. Use the charts on this page to explore Eiger BioPharmaceuticals's current cash history and peer comparisons.

Eiger BioPharmaceuticals's current cash decreased from $99M to $25M — a 74.3% year-over-year decrease (period ending December 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Eiger BioPharmaceuticals reported $25M in current cash as of December 2023. That compares with $99M in the prior-year period — down 74.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $25M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Eiger BioPharmaceuticals, and consider following EIGR for alerts when major investors trade the stock.

Eiger BioPharmaceuticals is classified in the Healthcare sector. On current cash, it currently shows $25M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing EIGR with unrelated industries.